8-K: Ovid Therapeutics Reports on Takeda's Phase 3 Soticlestat Study Results: Mixed Outcomes in Dravet and Lennox-Gastaut Syndromes

Ovid Therapeutics reports on Takeda's Phase 3 study results for soticlestat, which showed mixed outcomes with one study narrowly missing its primary endpoint while the other missed it entirely, but both showing positive secondary results and a favorable safety profile.

Summary

• Ovid Therapeutics has announced the topline results of Takeda's Phase 3 studies for soticlestat, a drug being investigated for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
• The SKYLINE study in Dravet syndrome narrowly missed its primary endpoint of reducing convulsive seizure frequency, with a p-value of 0.06.
• However, the SKYLINE study showed clinically meaningful and significant effects in multiple key secondary endpoints, all with p-values less than 0.008.
• The SKYWAY study in Lennox-Gastaut syndrome missed its primary endpoint of reducing major motor drop seizures.
• Soticlestat demonstrated a consistent and favorable safety and tolerability profile in both studies.
• Takeda plans to discuss the totality of the data with regulatory authorities to determine the next steps.
• Ovid has built a differentiated pipeline with novel programs, including two clinical programs (OV888 entering Phase 2 and OV329 completing a Phase 1) and a preclinical program (OV350 expected to enter the clinic in 2025).
• Ovid expects its cash runway to last into the first half of 2026 and anticipates several clinical milestones before then.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the disappointing primary endpoint results in both Phase 3 studies, despite positive secondary results and a favorable safety profile. The company's focus on its pipeline and financial discipline provides some positive outlook, but the overall tone is cautious.

Positives

• Soticlestat showed clinically meaningful and significant effects in multiple key secondary endpoints in the SKYLINE study for Dravet syndrome.
• Soticlestat had a consistent and favorable safety and tolerability profile in both the SKYLINE and SKYWAY studies.
• Ovid has a strong cash position expected to last into the first half of 2026.
• Ovid has a differentiated pipeline with multiple novel programs in development.
• Ovid anticipates several clinical milestones from its pipeline before the end of its cash runway.

Negatives

• The SKYLINE study narrowly missed its primary endpoint for Dravet syndrome.
• The SKYWAY study missed its primary endpoint for Lennox-Gastaut syndrome.
• The primary endpoint results for soticlestat were described as 'surprising and disappointing' by Ovid's CEO.

Risks

• The primary endpoint results for soticlestat in both studies were not as expected, which could impact regulatory approval.
• There is uncertainty regarding Takeda's next steps with soticlestat and potential regulatory filings.
• Ovid's future milestones and royalty payments from Takeda are dependent on the regulatory outcome of soticlestat.
• The success of Ovid's pipeline programs is subject to the inherent risks of clinical development and regulatory approval.

Future Outlook

Ovid expects its cash runway to last into the first half of 2026 and anticipates several clinical milestones from its pipeline before then. The company will prioritize activities and resources that have the most value-creating potential. Ovid will update its guidance relative to any potential milestones and royalty payments pursuant to its agreement with Takeda after Takeda determines its regulatory next steps.

Management Comments

• Dr. Jeremy Levin, Chairman and CEO of Ovid, stated, 'we are surprised and disappointed with the primary endpoint results'.
• Dr. Levin also stated, 'While SKYLINE narrowly missed its primary endpoint, we believe there are indications of effect in the secondary endpoints and the totality of the data in DS patients'.
• Dr. Levin remarked, 'Our R&D and financial strategy is independent of soticlestat's outcome. We will advance our pipeline thoughtfully and continue to apply the fiscal discipline to achieve our goals'.

Industry Context

The announcement is relevant to the broader pharmaceutical industry focused on developing treatments for rare epilepsies. The mixed results highlight the challenges in developing effective therapies for complex neurological conditions. The results will be closely watched by companies developing similar treatments and by investors in the rare disease space.

Comparison to Industry Standards

• The Phase 3 trials for soticlestat were designed to meet rigorous regulatory standards, similar to other pivotal trials for epilepsy treatments.
• The primary endpoint of seizure reduction is a common metric used in epilepsy trials, making the results directly comparable to other studies in the field.
• The use of placebo control groups and double-blind methodologies in the SKYLINE and SKYWAY trials aligns with industry best practices for clinical research.
• The secondary endpoints, including caregiver and clinician global impression of improvement, are also commonly used in epilepsy trials to assess the overall impact of treatment.
• The safety and tolerability profile of soticlestat is consistent with other anti-seizure medications, but the lack of drug-to-drug interactions is a positive differentiator.

Stakeholder Impact

• Shareholders may react negatively to the mixed results of the soticlestat studies.
• Patients with Dravet and Lennox-Gastaut syndromes may be disappointed by the primary endpoint results, but encouraged by the secondary endpoint results and safety profile.
• Employees of Ovid will continue to focus on advancing the company's pipeline programs.
• Takeda will need to evaluate the data and determine the next steps for soticlestat.

Next Steps

• Takeda will discuss the totality of the soticlestat data with regulatory authorities.
• Takeda will present the results of both Phase 3 studies at an upcoming scientific congress.
• Ovid will continue to advance its pipeline programs, including OV888, OV329, and OV350.
• Ovid will prioritize activities and resources that have the most value-creating potential.
• Ovid will update its guidance relative to any potential milestones and royalty payments after Takeda's regulatory discussions.

Key Dates

Keywords

soticlestat, Dravet syndrome, Lennox-Gastaut syndrome, epilepsy, clinical trials, Phase 3, Takeda, Ovid Therapeutics, OV888, OV329, OV350, seizures, regulatory approval